Timing is everything: new trial tests best duration of hormone therapy before breast cancer surgery
NCT ID NCT06806930
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how long hormone-blocking therapy given before surgery (neoadjuvant endocrine therapy) affects breast cancer in people with early-stage disease. About 90 participants will receive therapy for different lengths of time, from weeks up to a year. Researchers want to see if longer treatment leads to clearer surgical margins and better tumor response, and to develop a score that predicts outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neoadjuvant endocrine therapy (hormone-blocking drugs)
What this could lead to
If successful, this could help doctors personalize the duration of hormone therapy before breast cancer surgery, improving outcomes and reducing unnecessary treatment.
What could go wrong
This is a small, early-phase study (90 participants) focused on predicting response, not proving a cure. Results may not apply to all breast cancer types, and individual responses vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
George Washington-Medical Faculty Associates
RECRUITINGWashington D.C., District of Columbia, 20037, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••